Comirnaty Pfizer COVID
Selected indexed studies
- COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. (Eur Rev Med Pharmacol Sci, 2021) [PMID:33629336]
- BNT162b2 mRNA COVID-19 Vaccine: First Approval. (Drugs, 2021) [PMID:33683637]
- Role of COVID-19 Vaccines in SARS-CoV-2 Variants. (Front Immunol, 2022) [PMID:35669787]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. (2021) pubmed
- BNT162b2 mRNA COVID-19 Vaccine: First Approval. (2021) pubmed
- Role of COVID-19 Vaccines in SARS-CoV-2 Variants. (2022) pubmed
- Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. (2022) pubmed
- Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. (2024) pubmed
- Generalized Eruptive Keratoacanthoma (GEKA) after Pfizer mRNABNT162b2 (Comirnaty(®)) COVID-19 Vaccination Successfully Treated with Cemiplimab. (2024) pubmed
- Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions. (2022) pubmed
- Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine-a case report. (2022) pubmed
- A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine. (2024) pubmed
- Evaluation of the Effects of mRNA-COVID 19 Vaccines on Corneal Endothelium. (2025) pubmed